Optimal Cut-Off Values of Lymph Node Ratio Predicting Recurrence in Papillary Thyroid Cancer by 媛뺤긽�슧 et al.
icine®
ONAL STUDYMed
OBSERVATIOptimal Cut-Off Values of Lymph Node Ratio Predicting
Recurrence in Papillary Thyroid Cancer
Seul Gi Lee, MD, Joon Ho, MD, Jung Bum Choi, MD, Tae Hyung Kim, MD, Min Jhi Kim, MD,
ang-Wook Kang, MD g, MD,
unEun Jeong Ban, MD, Cho Rok Lee, MD, S
Kee-Hyun Nam, MD, PhD, Sang Geun Jo
confidence interval [CI]: 3.72–12.986, P< 0.001) and that tLNR
0.5 indicated a significantly increased risk of recurrence in patients
with N1b PTCs (HR: 2.372, 95% CI: 1.458–3.860, P< 0.001). In
a treatment plan; howe
eliminate confounding
tral and/or lateral LN
Editor: Yushan Zhang.
Received: November 4, 2015; revised: December 23, 2015; accepted:
January 12, 2016.
From the Departments of Surgery (SGL, JH, JBC, THK, MJK, EJB,
CRL,SWK, JJJ, KHN, WYC); Internal Medicine (YSJ), Open NBI
Convergence Technology Research Laboratory, Severance Hospital,
Yonsei Cancer Center, Yonsei University College of Medicine, Seoul
and Department of Gynecological Oncology (SGJ), Bundang CHA Medical
Center, CHA University, Gyeonggi-do, Republic of Korea.
Correspondence: Jandee Lee, Department of Surgery, Open NBI Con-
vergence Technology Research Laboratory, Yonsei Cancer Center,
Yonsei University College of Medicine, 134 Shinchon-dong, Seodae-
mun-ku, Seoul, Republic of Korea (e-mail: JANDEE@yuhs.ac).
SGL and JH equally contributed to this study.
This study was supported by the National Research Foundation of
Korea (NRF) grant funded by the Korea government (MEST)
(2014R1A1A2059343).
The authors have nothing to disclose.
The authors have no conflicts of interest to disclose.
Supplemental Digital Content is available for this article.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-ShareAlike 4.0 License, which
allows others to remix, tweak, and build upon the work non-commercially,
as long as the author is credited and the new creations are licensed under
the identical terms.
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000002692
Medicine  Volume 95, Number 5, February 2016, Jong Ju Jeon
g Suk Jo, MD,Jandee Lee, MD, PhD, and W
Abstract: Regional lymph node (LN) metastasis has a significant
impact for prediction of recurrence in patients with papillary thyroid
cancers (PTC); however, the prognostic value of the lymph node ratio
(LNR), which is defined as the ratio of the number of metastatic LNs to
the total number of investigated LNs, is controversial. In this study, we
determined the optimal cut-off values of LNRs for the prediction of
recurrence in PTC patients.
This large cohort study retrospectively evaluated 2294 patients who
had undergone total thyroidectomy for PTC at a single institution from
October 1985 to June 2009. The prediction probability of central LNR
(cLNR, level VI) and total LNR (tLNR, levels II–VI) were estimated by
binominal logistic regression analysis. Hazard ratios of the cut-off LNR
values for cancer recurrence were calculated for relevant covariates
using multivariate Cox regression analyses. Kaplan–Meier analyses
were also utilized to assess the effects of estimated LNR cut-off values
on recurrence-free survival (RFS).
Of the 2294 patients, 138 (6.0%) presented cancer recurrence during
the follow-up period (median duration¼ 107.1 months). The prediction
probability indicated that LNRs of 0.4 and 0.5 for central LN and total
LN, respectively, are optimal cut-off values for precise prediction
with minimization of outliers. Multivariate Cox regression analyses
revealed that cLNR0.4 was independently predictive of recurrence in
patients with N0 and N1a PTCs (hazard ratio [HR]: 7.016, 95%g, MD, PhD, Youn PhD,
ong Youn Chung, MD, PhD
addition, Kaplan–Meier analyses clearly demonstrated that these
LNR cut-off values are precisely operational in RFS estimation.
The cut-off LNR values of 0.4 and 0.5 for cLNR and tLNR,
respectively, were identified. Risk stratification combined with these
LNR cut-off values may prove useful to determine treatment and
follow-up strategies for PTC patients.
(Medicine 95(5):e2692)
Abbreviations: AJCC = American Joint Committee on Cancer,
CCND = central compartment node dissection, CI = confidence
interval, cLNR = central lymph node ratio, CT = computed
tomography, FNAB = fine needle aspiration biopsy, HR = hazard
ratio, LN = lymph node, LNR = lymph node ratio, MRND =
modified radical neck dissection, pN0 = positron emission
tomography-computed tomography, PTC = papillary thyroid
cancer, RAI = radioactive iodine, RFS = recurrence-free survival,
Tg = thyroglobulin, TgAb = anti-Tg antibody, tLNR = total lymph
node ratio, TT = total thyroidectomy, US = ultrasonography.
INTRODUCTION
P apillary thyroid cancer (PTC) is the most common endo-crine malignancy worldwide and elicits good therapeutic
response to surgery and/or radioiodine therapy; however, a
significant proportion of PTC patients experience recurrence
especially in neck lymph nodes (LNs).1–3 In fact, to predict the
clinical outcome of PTC, most clinicians utilize the inter-
national American Joint Committee on Cancer (AJCC) tumor,
node, metastases (TNM) staging system, but this classical
classification system cannot precisely predict nodal recurrence
of patients with PTC, as this system was designed to predict
patient mortality.4–6
Recently, the American Thyroid Association (ATA) pro-
posed that the number and the size of metastatic LNs in the neck
can be an important predictor for recurrence of PTC.7,8 There-
fore, complete evaluation including the number and the size of
metastatic LNs in PTC has become more important for the
determination of exact tumor stage, direction of appropriate
adjuvant treatment plans, and prediction of long-term prog-
nosis, including nodal recurrence. In addition to the number and
the size of metastatic LNs, the ratio of metastatic LNs to
examined LNs (lymph node ratio, LNR) has been suggested
by several groups to be useful to predict PTC recurrence.9–12
Creation of a personalized treatment plan is primarily
based on individualized risk estimation of recurrence and
disease-specific mortality. Thus, a better refinement of LN
metastasis using the LNR would be influential in creating suchver, previous studies have been unable to
factors caused by inhomogeneous cen-
dissection yield.10,13 Furthermore, the
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tasis as well as to selected patients with high serumoptimal LNR cut-off value that will predict tumor recurrence
remains undetermined.12,14,15 In this study, we analyzed clin-
icopathological parameters in a large cohort of PTC patients
who underwent total thyroidectomy (TT) and central compart-
ment node dissection (CCND) with or without modified radical
neck dissection (MRND) in a single tertiary referral hospital. To
determine the optimal LNR cut-off value for PTC, we also
performed statistical analyses to estimate the prediction prob-
abilities of LNRs and to calculate recurrence-free survival
(RFS) using the defined optimal LNR cut-off value.
MATERIALS AND METHODS
Study Subjects
The medical records of 2750 PTC patients who underwent
TTwith CCND orMRND between October 1985 and June 2009
were retrospectively analyzed. Clinico-pathological
parameters, including number of metastatic LNs and LN dis-
section yield at the initial operation, were collected from the
database of our institution. To investigate the long-term effects
of LNRs on PTC recurrence in a homogenous patient cohort, we
designed the study protocol as shown in Figure 1. Of the 2750
patients, 176 (6.4%) were excluded as a result of inadequate
follow-up duration (<5 years) and 25 (0.9%) were excluded
because they were too young or too old (aged13 years or76
years) at baseline. Of the remaining 2549 patients, 1829
(71.8%) with tumors classified as N0 or N1a underwent TT
with CCND, whereas the remaining 720 (28.2%) with tumors
classified as N1b underwent TT with MRND. To ensure ade-
quate cervical LN dissection yield, patients with<6 central LNs
harvested by CCND (n¼175, 9.6%) and <18 total LNs har-
vested by MRND (n¼80, 11.1%) were excluded. Therefore,
2294 patients were eligible for analysis. The study protocol was
Lee et alapproved by the local institutional review board, which waived
the requirement for informed consent due to the retrospective
nature of this study.
FIGURE 1. Flow diagram outlining the study protocol.
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Following complete radiologic and histologic examin-
ations, the extent of thyroidectomy in all patients with PTC
was determined using ATA guidelines13. Cervical LNs in levels
II–VI were evaluated preoperatively by neck ultrasonography
(US) and computed tomography (CT). Patients underwent
CCND (level VI; pretracheal, prelaryngeal, and paraesophageal
LNs) prophylactically for accurate staging of PTC and for
management of subclinical LN metastasis or therapeutically
for clinically suspicious LNs. For the lateral (levels II-V) neck
compartment, patients preoperatively presenting with clinical
LN metastasis underwent therapeutic MRND.
Excluding those with T1N0M0 tumors, patients who
underwent TT received low-dose (1.1 GBq) radioactive iodine
(RAI) for remnant ablation at 4 to 8 weeks after surgery. At 5 to
7 days after RAI treatment with T4 withdrawal or rhTSH
injection, serum thyroglobulin (Tg) and anti-thyroglobulin anti-
body (TgAb) concentrations were measured, and post-ablation
whole body scans (WBS) were performed. High-dose RAI
(3.7–5.5 GBq) was recommended to patients with more aggres-
sive tumor histology (T4 or N1b stage) or initial distant metas-
Medicine  Volume 95, Number 5, February 2016thyroglobulin (Tg) levels yet without definite metastatic lesions,
after RAI WBS.
Follow-Up Protocol
Patients underwent radioactive iodine (RAI) ablation about
1 to 3 months after surgery using a dose based on ATA
guidelines.16 Patients were then examined by physical exam-
ination, neck US, and measurement of serum Tg and anti-Tg
antibody (TgAb) concentrations at 3 and 6 months and annually
thereafter. Patients with evidence of recurrence or distant
metastasis were assessed by additional imaging modalities,
including neck CT and/or positron emission tomography-com-
puted tomography (PET-CT). Structural disease recurrence was
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
98.7%, P< 0.001) RFS rates than patients with cLNR< 0.4
(Figure 3A). In addition, in the MRND group, patients with
tLNR 0.5 had significantly lower 5-year (73.8% vs 93.9%,
FIGURE 2. Prediction probability of lymph node ratio (LNR) usingconfirmed by imaging modalities and/or by pathological diag-
nosis using US-guided fine needle aspiration biopsy (FNAB).
Measurement of LNR
Whole surgical specimens were analyzed histologically to
determine tumor characteristics and to assess the presence of
LN metastasis. The pathologic LN status of these specimens
was reassessed independently by 2 experienced pathologists.
Pathologic N0 (pN0) was defined as the absence of metastatic
foci in the harvested cervical LN, whereas pN1a and pN1b were
defined as the presence of metastatic LNs among any retrieved
central and lateral LNs, respectively. LNR was defined as the
total number of metastatic LNs divided by the total number of
LNs retrieved from the central compartment (level VI) alone
(cLNR¼ number of metastatic LNs/number of dissected LNs in
level VI) and from the central and lateral compartments (levels
II–VI; tLNR ¼ number of metastatic LNs/number of dissected
node in LNs in level II–VI).
Statistical Analysis
Rates and proportions were calculated for categorical data,
whereas means  SDs were calculated for continuous data.
Groups were compared using Student’s t test, chi-square test, or
Wilcoxon rank sum test as appropriate. RFS was defined as the
time from the date of surgery to the date of first detection of
structural recurrent disease. Binominal logistic regression
analysis was used to calculate the predicted probability function
of recurrence for each LNR, and threshold cLNR and tLNR
were selected. Univariate analyses were utilized to determine
factors significantly associated with recurrence; factors ana-
lyzed included patient age and gender; tumor size; extrathyr-
oidal extension; pathologic T-, N-, M-, and TNM-stages; and
predicted LNR. Factors that proved significant by univariate
analysis were entered into multivariate analysis by logistic
regression to determine factors independently associated with
tumor recurrence. Survival curves were calculated according to
the Kaplan–Meier method and compared by the log-rank test.
All P values<0.05 were considered statistically significant. All
statistical analyses were performed using IBM SPSS statistics
20.0 (SPSS Inc., Chicago, IL).
RESULTS
Characteristics of the Study Patients
Of the 2294patientswho fulfilled the selection criteria, 1654
(72.1%) underwent TT with CCND and 640 (27.9%) underwent
TTwithMRND. The baseline characteristics of these patients are
shown in Supplementary Table 1, http://links.lww.com/MD/
A668. Study patients were mostly women (87.5%). The mean
ageat timeof surgerywas 44.6 12.0 years (range, 13–76years),
and mean tumor size was 14.8 9.5mm (range, 6.0–80.0mm).
The ablation success rate parameters of study patients at low- or
high-dose RAI ablation after surgery are presented in Supple-
mentary Table 2, http://links.lww.com/MD/A668.
Median follow-up duration was 107.1 months (range, 72–
289 months) at the time of the last clinic visit. At the time of last
follow-up, 17 patients (0.7%) had died due to disease-specific
causes. Structural recurrence was observed in 138 (6.0%)
patients, and 133 (5.8%) showed locoregional recurrence with
128 (5.6%) in regional LNs and 5 (0.2%) in the operative bed.
Medicine  Volume 95, Number 5, February 2016All of these local recurrences were confirmed by cytological
reports. Five patients (0.2%) developed distant spreading during
the follow-up period.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Estimation of the Optimal LNR Cut-Off Values
Based on the presence of metastatic LNs, 787 patients
(34.3%) were classified as pN0, 867 (37.8%) as pN1a, and 640
(27.9%) as pN1b. The 10-year RFS rates for these groups were
99.3%, 92.6%, and 81.8%, respectively (P< 0.001). LNRs were
calculated for the total number of central LNs in the CCND
group (cLNR) and the total number of central and lateral LNs
(levels II-VI) in the MRND group (tLNR). The mean cLNR and
tLNR were 0.20 0.27 and 0.31 0.17, respectively (Supple-
mentary Table 3, http://links.lww.com/MD/A668). The prob-
ability function displayed an exponential pattern, indicating that
the probability of an event increases exponentially with increas-
ing LNR. The threshold LNRs of 0.4 and 0.5 were at the
inflection points of the curves without outliers (Figure 2). When
we excluded the pN0 patients, the probability function also
indicated an exponential pattern, and the inflection points of the
curves were 0.2 and 0.8 (Supplementary Figure 1, http://
links.lww.com/MD/A668). However, as our study goal was
to find the optimal cut-off value for a clinical setting and we
had performed CCND for prophylactic and therapeutic pur-
poses, we decided to include the pN0 patients in the analysis of
the CCND group.
Relationship Between LNRs and RFS
In the Kaplan–Meier analysis, RFS rates were signifi-
cantly decreased in the higher cLNR or tLNR categories. In the
CCND group, patients with cLNR0.4 had significantly lower
5-year (93.9% vs 99.2%, P< 0.001) and 10-year (86.8% vs
Proposed Lymph Node Ratio in Thyroid Cancerbinominal logistic regression analysis. The optimal cutoffs were
determined to be 0.4 for cLNR (A) and 0.5 for tLNR (B).
cLNR¼ central lymph node ratio, LNR¼ lymph node ratio,
tLNR¼ total lymph node ratio.
www.md-journal.com | 3
FIGURE 3. Comparison of 5-year and 10-year RFS between LN
ratio <0.4 and 0.4 in CCND group (A) and LN ratio <0.5 and
Lee et alP< 0.001) and 10-year (58.4% vs 93.2%, P< 0.001) RFS rates
than patients with tLNR< 0.5 (Figure 3B).
Univariate analyses were performed to identify clinical
and pathological factors that are predictive of 5- and 10-year
RFS. In the CCND group, larger tumor size; extrathyroidal
invasion; higher pT-, pN-, pM- and TNM-stages; and cLNR
(0.4) were significantly associated with recurrence (Table 1).
In theMRND group, male gender, larger tumor size, pM1-stage,
and tLNR (0.5) were significantly associated with recurrence
(Table 2). Multivariate Cox’s regression analyses revealed that
all clinicopathologic parameters correlated significantly with
RFS in univariate analysis were independent prognostic factors
in both the CCND and MRND groups. Interestingly, log-rank
tests indicated that the hazard ratio (HR) of high cLNR (HR:
7.016, 95% confidence interval [CI]: 3.792–12.983, P< 0.001)
was higher than that of pN stage (HR: 4.796, 95% CI: 2.146–
10.719, P< 0.001) in the CCND group (Table 3). In the MRND
group, high tLNR (0.5) significantly increased the risk of PTC
recurrence (HR: 2.372, 95% CI: 1.458–3.860), whereas pN
0.5 in MRND group (B). CCND¼ central compartment node
dissection, LN ratio¼ lymph node ratio, MRND¼modified radical
neck dissection, RFS¼ recurrence-free survival.classification had no statistically significant impact, indicating
that LNRs may be a more useful predictor for recurrence than
the pN designation (Table 4).
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LN metastases are frequently observed in patients with
PTC and occur in anyway from 20% to 70% of patients
depending on the definition of LN metastases, due to the high
prevalence of subclinical metastases.17–19 Although many
investigators propose that clinically detectable metastatic
LNs are associated with tumor recurrence, the role of prophy-
lactic CCND to completely remove all potentially subclinical
disease remains unclear. Prophylactic CCND, however, has
been reported to reduce the likelihood of central neck recur-
rence, because neck US has a limited ability to evaluate these
central compartment LNs preoperatively and micrometastatic
LNs are detected in up to 90% of these patients.2,19–22 Prophy-
lactic CCND may, however, increase complications, while
simultaneously imparting questionable therapeutic impacts on
patients without clinically apparent disease in LNs.2,16,18,19,22
As controversy regarding the role of prophylactic CCND con-
tinues, finding an optimal approach to determine detailed LN
status in patients with PTC has been regarded as a critical step to
enhance the staging accuracy, to choose appropriate adjuvant
treatments, and finally to predict long-term patient prognosis.
Based on this information, all patients who underwent TT
according to ATA guidelines have also undergone routine
prophylactic CCND at our institution. As a result, our surgical
treatment policy provides complete removal of all potential
metastatic lesions in level VI LNs.
The number of LNs examined has been regarded as a
surrogate measure of the extent of dissection in different
nodal basins.9,12,23–26 Maximizing the number of LNs
retrieved during thyroid cancer surgery has been reported
to increase the likelihood of complete remission and reduce
the incidence of recurrence;12,24 however, LNR is influenced
not only by the disease burden but also by the extent of the
neck dissection and pathologic examination. Therefore, it is
important to determine whether a minimum number of LNs
should be harvested during cervical LN dissection to achieve
an adequate operative yield and decrease the risk of recur-
rence. Several previous studies evaluated the LNR of cases of
thyroid cancer from which >3 LNs were harvested.10,13
However, many variations have been reported in the mini-
mum number of LNs required to determine proper LNR
criteria in thyroid cancer surgery. For example, 1 previous
study included patients with >4 LNs, whereas another
included those with >6 LNs.12,14,15 These confusing results
have demonstrated the difficulty in suggesting the proper
criteria for determining the minimum number of LNs to be
removed in thyroid cancer surgery. As the lymph node yield
(LNY) is an indicator for adequate staging, we can expect
that the smaller the number of LNs harvested, the higher
the probability that metastatic nodal disease would be left
unresected. It is reasonable to assume that such unresected
disease may contribute not only to local recurrence but to
long-term prognosis as well. Several studies have found
that the risk of recurrence is positively associated with a
higher number of LN metastases at initial presentation.
Leboulleux et al reported that the 10-year risk of recurrence
was significantly higher in patients with >10 metastatic LNs
(21%) than in patients with< 5 LN metastases (3%).27 Like-
wise, Sugitani et al demonstrated that the risk of recurrence
was significantly higher in patients with >5 LN metastases
Medicine  Volume 95, Number 5, February 2016(19%) that in those with< 5 LN metastases (8%).28 Accord-
ing to these results, the ATA Surgical Affairs Committee’s
Taskforce concluded via meta-analysis that the median risk
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Univariate Analysis of Prognostic Factors for Recurrence-Free Survival in PTC Patients who Underwent Total
Thyroidectomy with CCND (N¼1654)
Variable Number Percentage of 5-year RFS P Value

Percentage of 10-Year RFS P Value

Age, y
<45 755 98.2 0.612 95.1 0.554
45 899 98.1 93.0
Gender
Female 1492 98.3 0.185 98.2 0.299
Male 162 97.5 91.9
Tumor size (mm)
10 895 98.9 0.106 98.9 <0.001
>10 759 97.3 92.7
Histologic subtype
Conventional PTC 1289 97.9 97.8 0.257
Follicular variant PTC 319 99.0 0.390 99.0
Other variants of PTC

46 87.5 61.2
Multifocality
Absent 954 98.6 0.318 98.5 0.284
Present 700 97.6 97.6
Bilaterality
Absent 1128 98.5 0.394 95.4 0.267
Present 526 97.5 95.3
Extrathyroidal extension
Absent 644 98.9 0.075 96.9 0.001
Present 1010 97.7 90.6
pT classification
T1 596 99.0 99.0 0.001
T2 43 99.0 0.015 98.1
T3 968 97.8 95.5
T4a 46 78.1 67.0
T4b 1 0 0
pN classification
N0 780 99.5 0.003 99.5 <0.001
N1a 825 96.9 92.6
LNR (0.4)
<0.4 1301 99.2 <0.001 98.7 <0.001
0.4 353 93.9 86.8
pM classification
M0 1651 98.4 <0.001 95.6 <0.001
M1 3 0 0
TNM stage
I 944 98.5 97.0
II 4 75.0 62.0
III 647 98.3 <0.001 95.1 <0.001
IVa 34 70.4 26.1
IVb 1 0 0
IVc 2 0 0
CCND¼ central compartment node dissection, LNR¼ ratio of metastatic to examined lymph nodes, PTC¼ papillary thyroid cancer, RFS¼ re-
, co
Medicine  Volume 95, Number 5, February 2016 Proposed Lymph Node Ratio in Thyroid Cancerof recurrence in papillary thyroid cancer patients varies
markedly according to the number of positive nodes
(<5 nodes: 4% [range 3%–8%] vs >5 nodes: 19%, [range
7%–21%]).29 Taken together, we decided on a cut-off of at
least 6 central LNs in the CCND group based on the criteria
of recurrence risk determined by the ATA Taskforce. This
recurrence-free survival.
P value: log-rank test.
Other variants of PTC: tall cell variant, diffuse sclerosing variantcut-off range of LNs may provide the proper LNY and thus
minimize the variations in surgical and pathologic factors
used to determine LNR.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Several staging systems have been developed to identify
reliable clinico-pathological factors that can be used to stratify
patients relative to outcomes and to propose proper long-term
management for patients with PTC.1,4–6,16 The staging
accuracy of these systems has profound variations that originate
from practical issues, such as completeness of potential meta-
lumnar variant, and solid variant of PTC.static LNs removal, or from the characteristics of the staging
system itself, such as oversimplification of metastatic cervical
LNs. In the case of the AJCC TNM staging system, cervical LN
www.md-journal.com | 5
TABLE 2. Univariate Analysis of Prognostic Factors for Recurrence-Free Survival in PTC Patients who Underwent Total
Thyroidectomy with MRND (N¼720)
Variable Number Percentage of 5-Year RFS P Value

Percentage of 10-Year RFS P Value

Age, y
<45 377 92.4 0.219 91.0 0.667
45 263 98.1 85.6
Gender
Female 515 93.4 0.412 92.8 0.004
Male 125 91.9 84.4
Tumor size, mm
10 895 98.9 0.328 97.5 <0.001
>10 759 97.3 90.7
Histologic subtype
Conventional PTC 468 91.9 0.146 90.3 0.078
Follicular variant PTC 149 94.9 90.5
Other variants of PTC

23 87.0 62.7
Multifocality
Absent 316 98.1 0.904 92.8 0.518
Present 324 97.6 90.7
Bilaterality
Absent 399 93.5 0.315 92.6 0.102
Present 241 88.5 87.8
Extrathyroidal extension
Absent 117 94.8 0.472 66.8 0.099
Present 526 93.2 90.1
pT classification
T1 91 91.5 0.348 87.6 0.176
T2 24 82.0 72.1
T3 464 91.8 90.4
T4a 52 78.1 20.8
T4b 9 44.4 0
LNR (0.5)
<0.5 555 93.9 <0.001 93.2 <0.001
0.5 85 73.8 58.4
pM classification
M0 626 94.7 <0.001 92.7 <0.001
M1 14 35.7 0
TNM stage
I 351 93.8 0.104 45.7 0.067
II 9 66.7 65.6
III 2 92.0 90.6
IVa 269 78.1 50.4
IVb 3 44.4 0
IVc 6 16.7 0
LNR¼ ratio of metastatic to examined lymph nodes, MRND¼modified radical neck dissection, PTC¼ papillary thyroid cancer, RFS¼ recur-
recurrence-free survival.
co
Lee et al Medicine  Volume 95, Number 5, February 2016metastases are categorized into only 2 groups: N1a (level VI) or
N1b (levels II–V and VII).5,6 Actually, the AJCC TNM staging
system classifies the metastatic LNs based on cervical anatom-
ical compartment, but this system does not reflect the extent of
LN involvement, as the number of metastatic LNs has no impact
on pN stage.
To improve the predictive ability of LN status, the LNR has
been assessed in patients with PTC, and most studies indicated

P value: log-rank test
Other variants of PTC: tall cell variant, diffuse sclerosing variant,that the LNR category is independently prognostic, more so than
the conventional AJCC TNM staging system.4,9–11,23,30Whether
LNR is a better predictor than the AJCC pN category alone,
6 | www.md-journal.comhowever, remains unknown. Thus, we sought to determine the
optimal cut-off LNRs for long-term (5 and 10 year) prediction of
RFS in a large number of patients with PTC. We found that a
cLNR of 0.4 was the optimal cut-off value in patients who
underwent CCND of at least 6 dissected central LNs. Further-
more, a tLNR of 0.5 was also optimal in patients who underwent
MRND with at least 18 total harvested LNs. Using these cut-off
values, we found that even after adjusting for other significant
lumnar variant, and solid variant of PTC.prognostic factors of RFS, these cLNR and tLNR values pre-
dicted the risk of recurrence of PTC and exhibited an independent
association with RFS.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 3. Multivariate Analysis (Cox Proportional Hazard
Model) of Prognostic Factors for RFS in PTC Patients who
Underwent Total Thyroidectomy with CCND (N¼1654)
Variable HR CI P Value
Tumor size 3.751 1.852–7.596 <0.001
Extrathyroidal extension 3.691 1.656–8.225 0.001
pT classification
T1 0.537 1.234–3.226 0.004
T2 1.168 1.514–3.691
T3 2.685 2.541–4.534
T4a 15.470 1.425–18.214
pN classification 4.796 2.146–10.719 <0.001
LNR (0.4) 7.016 3.792–12.983 <0.001
pM classification 16.650 1.012–17.807 <0.001
TNM stage
I 1.027 0.601–1.102 <0.001
II 1.343 1.102–1.514
III 1.754 1.257–1.942
IVa 2.212 1.322–2.215
IVb 9.615 1.512–15.812
IVc 13.125 1.814–19.512
CCND¼ central compartment node dissection, CI¼ confidence
interval, HR¼ hazard ratio, LNR¼ ratio of metastatic to examined
Medicine  Volume 95, Number 5, February 2016Recently, as our understanding of the molecular biological
aspect of thyroid carcinogenesis has markedly improved, tar-
geted agents such as sorafenib (Nexavar1), vemurafenib, tra-
metinib, and dabrafenib have been investigated and developed
for the purpose of treating recurrent or persistent PTC.31 In
addition to the discoveries of new drugs, molecular markers to
support precise diagnosis and predict poor prognosis have also
been studied, such as the BRAFV600E mutation and TERT
promoter mutation.32–34 Coupling with these new advances in
molecular markers, the assessment of LNR after surgical treat-
ment could improve the predictability of PTC prognosis in
future studies.
Although this study revealed numerous important positive
findings, this study had several limitations, including its retro-
lymph nodes, PTC¼ papillary thyroid cancer, RFS¼ recurrence-free
survival.spective design and performance at a single center. Even within
a single institution, surgical skills and pathologic assessments
may vary. This study attempted to minimize these drawbacks by
TABLE 4. Multivariate Analysis (Cox Proportional Hazard
Model) of Prognostic Factors for RFS in PTC Patients who
Underwent Total Thyroidectomy with MRND (N¼720)
Variable HR CI P Value
Gender 2.016 1.241–3.275 0.005
Tumor size 1.665 0.935–2.965 0.083
LNR (0.5) 2.372 1.458–3.860 0.001
pM classification 13.680 6.776–27.620 <0.001
CI¼ confidence interval, HR¼ hazard ratio, LNR¼ ratio of
metastatic to examined lymph nodes, MRND¼modified radical neck
dissection, PTC¼ papillary thyroid cancer, RFS¼ recurrence-free
survival.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.adjusting LNR and LN yield for the extent of neck dissection.
Furthermore, we included only those patients from whom at
least 6 central LNs or 18 central and lateral LNs were harvested.
The median follow-up period in this study was only 107months,
which was likely not long enough to completely determine RFS
rates in patients with PTC, a cancer that can recur decades after
initial treatment. Another unresolved issue in the present work
waswhether patient ablation using high-doseRAI (3.7–5.5GBq)
would have an impact on long-term outcomes, compared with
patients who did not undergo high-dose RAI ablation. Our results
indicate that further clinical trials are needed to define the
effectiveness of RAI ablation. Finally, this study included
patients who underwent prophylactic CCND. Due to the insuffi-
cient data for patients without prophylactic CCND, the potential
role of prophylactic CCND in PTC patients remains a subject of
debate. In the future, large multicenter studies may provide
further evidence of the ability of threshold LNR values to predict
recurrence and influence postoperative treatment in patients
with PTC.
In conclusion, our study assessed the ability of LNR to
predict RFS in patients with PTC. A cut-off LNR of 0.4 in
CCND patients and 0.5 in MRND patients were significant
independent predictors of disease recurrence and may be
superior to using known risk factors, including pN stage, as
predictors. These findings suggest that assessment of proper
cut-off LNRs, combined with existing staging systems and
prognostic variables, will aid the determination of further
treatment and follow-up strategies in patients with PTC.
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